Literature DB >> 1311035

Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.

S Okazumi1, K Isono, K Enomoto, T Kikuchi, M Ozaki, H Yamamoto, H Hayashi, T Asano, M Ryu.   

Abstract

To evaluate glucose metabolism in patients with tumors involving the liver, 35 patients with liver lesions had PET using 18F-2-fluoro-2-deoxy-D-glucose (FDG). FDG (148 MBq) was injected and radioactivity of the tumor was scanned dynamically by PET. The rate constants (k1, k2, k3, k4) of FDG in a metabolic model were calculated. The results were compared to hexokinase activity in the excised tumor specimens. k3 was found to reflect tumor hexokinase activity. When k3 was used as an index (cut-off value: 0.025), it was possible to distinguish benign and malignant tumors. k4 was significantly higher in hepatocellular carcinoma. By using k3 and k4 as indices, one could assess the degree of differentiation of hepatocellular carcinoma. After treatment, k3 decreased according to the effectiveness of therapy and thus may be a useful index for quantitatively assessing tumor viability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311035

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  70 in total

1.  PET scan with 11C-acetate for the imaging of liver masses: report of a false positive case.

Authors:  R Lhommel; L Annet; A Bol; J-F Gigot; C Sempoux; I Mathieu; M Seret; M Lonneux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

2.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

3.  Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake.

Authors:  V Arena; A Skanjeti; R Casoni; A Douroukas; E Pelosi
Journal:  Radiol Med       Date:  2008-07-10       Impact factor: 3.469

4.  Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria.

Authors:  Seung Duk Lee; Bora Lee; Seong Hoon Kim; Jungnam Joo; Seok-Ki Kim; Young-Kyu Kim; Sang-Jae Park
Journal:  World J Transplant       Date:  2016-06-24

5.  A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy.

Authors:  Kristen A Wangerin; Mark Muzi; Lanell M Peterson; Hannah M Linden; Alena Novakova; David A Mankoff; Paul E Kinahan
Journal:  Phys Med Biol       Date:  2017-02-13       Impact factor: 3.609

6.  Structural and practical identifiability of dual-input kinetic modeling in dynamic PET of liver inflammation.

Authors:  Yang Zuo; Souvik Sarkar; Michael T Corwin; Kristin Olson; Ramsey D Badawi; Guobao Wang
Journal:  Phys Med Biol       Date:  2019-09-05       Impact factor: 3.609

7.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

8.  Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.

Authors:  S Yasuda; S Raja; K F Hubner
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Regional lung derecruitment and inflammation during 16 hours of mechanical ventilation in supine healthy sheep.

Authors:  Mauro R Tucci; Eduardo L V Costa; Tyler J Wellman; Guido Musch; Tilo Winkler; R Scott Harris; Jose G Venegas; Marcelo B P Amato; Marcos F Vidal Melo
Journal:  Anesthesiology       Date:  2013-07       Impact factor: 7.892

10.  FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.

Authors:  Tatsuya Higashi; Etsuro Hatano; Iwao Ikai; Ryuichi Nishii; Yuji Nakamoto; Koichi Ishizu; Tsuyoshi Suga; Hidekazu Kawashima; Kaori Togashi; Satoru Seo; Koji Kitamura; Yasutsugu Takada; Yasuji Takada; Shinji Uemoto; Shinji Kamimoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.